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Abstract     
The treatment of cancer by Chemotherapy has become a new focus in cancer research and treatment in 
Cancerous cases, Natural killer, CD8
+
 and Cytotoxic lymphocytes alone cannot effectively kill cancer cells and 
thus the need for chemotherapy administration in this study, we propose analytical solutions to the modified 
Jackson, T. L. (2002), model that included chemotherapy but particularly chemotherapy on vascular tumor 
growth. We applied Duhamel principle and carried out couple of analysis on the solutions of the modeled 
equations for various treatments using the therapy. The results from the analysis portend good revelations on 
cancer cell management and control using chemotherapy. 
Keywords:Tomur, malignant, chemotherapy, Duhamel, Apoptosis, Angiogenesis, Vasculature, Carcinogenesis, 
Perturbation  
 
1.1 INTRODUCTION 
Tumour is an abnormal swelling in or on any part of the body. It is one of the classical signs of inflammation in a 
tissue. The swelling of an inflamed area is sometimes due to the leakage from small blood vessels of clear 
proteins containing fluid, which accumulates between the cells. The term tumour is applied to abnormal growth 
of tissue, which may be benign or malignant. Cancer is the common term for all malignant tumours; it probably 
derives from the Latin word for crab, “cancer” presumably because cancer adheres to any part of the body that it 
affects in an obstinate manner like the crab. When cancer cells that invade the blood stream are transported to 
another location thus creating a secondary tumour or metastases, it may be difficult to treat, because treatment 
may damage the normal tissue. 
The mathematical model derived by de Pillis et al (2002) was solved Numerically and we feel that the 
models can be solved rather analytically to give better result. We know that numerical solutions are approximate 
solutions and in cancer treatment, approximate solution could be dangerous. As such, we revisited the models 
with some tractable assumptions to enable us solve the equations analytically. 
Recently, records from all over the world show high rise in cancer incidence. Our hospitals are 
witnessing new cases of cancers, at least an average of more than one every day. According to American Cancer 
Society estimates, cancer caused approximately 538,000 deaths in 2004 accounting for about 23% of all deaths 
in the United States of America alone. 
The conventional methods of treating cancer (Surgery, chemotherapy, radiation, proton therapy ETC) 
are not helping matters because they come with their attending negative side effects, which can also lead to death 
of patient receiving treatment. To this ends, our aim is to analyse existing mathematical models to help us 
understand the interaction between the immune and cancer cells and the effects of chemotherapy on the growth 
rate of tumor and also to help us predict incidence of cancer on the host. This in turn can lead to better treatment 
and increase in survival rate and quality of life for those struggling with cancer 
In this research work, we shall be considering the mathematical models on the new treatment method; 
the combination methods. One major question that we hope to shed light on, by modeling cancer treatments, is 
how immunotherapy and chemotherapy interact. We also plan to simulate our solutions to see the behaviour of 
our models, after series of perturbations. Although we do not have exact experimental results, we hope that the 
simulation of our results show reasonable behaviour 
The concepts of mathematical modeling of tumour is new in the field of Applied Mathematics. 
However, for 15 –years now many mathematical models of tumour growth and invasion have started appearing 
in the research papers. 
According to Sanga et al (2006), mathematical modeling and simulation are tools that can provide a 
robust framework for better understanding of cancer progression and response to chemotherapy. Quaranta V; 
Weaver A. M; cummings, TT; Anderson AR (2005), are of the view that quantitative simulation of clinically 
relevant cancer situation based on experimentally validated mathematical model, provides an opportunity for the 
researchers, and eventually the clinician, to address data and information in the context of well formulated 
question, and “what if” scenarios. They pointed out that cancer research has undergone changes in the past few 
years, producing information, both at the basic and clinical levels. However, this is no longer the issue, rather 
how to handle this information has become the major obstacle to progress. Initiative approaches are no longer 
feasible. The next big step will be to implement mathematical modeling approaches to analyse the enormous 
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amount of data being produced and extract useful answers, a top-down approach to biology and medicine. 
Moreover, as shown in the recent paper of Novozhilove, A. S., Fiana S. Berezouskaya; Bugene V. 
Koonin And Georgy P. Kareu (2006),  Oncolytic viruses that specifically target tumour cells are promising anti-
cancer therapeutic agents. The interaction between an oncolytic virus and tumour cells is amenable to 
mathematics and modeling using adaptation of techniques employed previously for modeling other type of virus-
cell interaction. Their model exhibits all possible outcomes of oncolytic virus infection i.e. no effect on the 
tumour, stabilization or reduction of the tumour load and complete elimination of the tumour. The parameter 
values that result in tumour elimination, which is obviously, the desired outcome are compatible with some of 
the available experimental data. 
Ribba B., Therry Colin and Santiago Schnell (2006), have shown that Radiotherapy outcomes are 
usually predicted using the quadratic model. However, this model does not integrate complex cell cycle 
regulation growth based on the genetic and molecular features of the evolution of colorectal cancer. The model 
includes key genes, cellular kinetics tissue dynamics, and macroscopic tumour evolution and radio sensitivity 
dependence on the cell cycle phase. They investigate the role of gene-dependent cell cycle regulation in the 
response of tumours to therapeutic irradiation protocols. Their model provides insight into the coupling of 
complex biological processes, which leads to a better understanding of on cogenesis. This hopefully will lead to 
improved radiation therapy. 
Mathematical models of cancer growth have been the subject of research activity for many years. The 
Gompertzian model, logistic and power functions have been used, to describe tumour growth dynamics. These 
formalisms have been used to investigate different therapeutic strategies such as antiogiogenic or radiation 
treatments. 
The work by Orme, M. C. and Chaplain, M. A. J. (2003) reveal that a spherical tumour growth and 
invasion with regard to the parent blood vessel vascularization, may consequently lead to metastasis. Their 
model described the case where the invasive tumour cells growth advancing toward the parent blood vessel were 
unable to reach some parts of the tumour due to competition for space with tumour cells or high internal pressure 
which may cause blood vessels to collapse. Fisher, et al., (2004) used epidemiological data to infer that cancer 
incidence increases with approximately the sixth power of age. They recognize that the rate of cancer occurrence 
would rise with the nth power of age if transformation required n + 1 independent steps. They further suggest 
that, about seven cells had to be transformed independently. This would give the observed rate of change with 
age. However, Armitage and Doll (2002) pointed out that if transformation happens by one-step in each of 
several independent cells, then tumour incidence should increase with about the sixth power of carcinogen dose. 
Alexey S. Matveev and Andrey V. Savkin (2005); studied cancer chemotherapy with the application of 
several drugs and, the influence of tumours on normal cells and optimal chemotherapy regimes. The model 
indicates that the presence of tumour inhibiting the growth of normal cells in the context of multi-drug therapy 
may complicate the protocol. They stated that optimal drug delivery strategies are separate. Some researchers in 
this area justify benefits from the late intensification of the chemotherapy. Other authors proceeding from 
biological features different from the negative influence of tumours on the patient have concluded that early 
intensification of therapy is optimal. 
Chattler (2004) formulated a mathematical model for cancer chemotherapy treatment when a single 
G2/M specific killing agent was considered as the optimal control problem. Their results show that geometric 
properties of the model have a direct influence on the type of controls, which are optimal. Singular arcs are not 
optimal if linear models are used, but for more general PK–models and PD functions, S, this does not necessarily 
hold, but true for regions where S is strictly convex. The optimality concentration changes as S becomes concave. 
Byrne, H. M., Chaplain M. A. J., Pettet, G. J. and McELWAIN D. L. S. (1999) examined angiogenesis 
of tumour in terms of continuous variables which yielded qualitative phenomenological result. Their model was 
based or rooted in the work of Balding and McElwair (1985) which was developed from a fungal growth model 
proposed by Edelstain (1982). Their work has the ability to predict the brush-border effect of the advancing 
vascular front that has been worked upon by Muthukkaruppani et al (1982) 
Mathematical modeling of deterministic reaction-diffusion equations have been used to model the 
spatial spread of tumour both at an early stage in its growth by Sheriatt and Nowak, (1992); Ward, J. P. and King 
J. R. (1999) and at the later invasive stage of tumour development by Orme and Chaplain (1996); Gatenby and 
Gawlinski (1996); Perumpanani et al, (1996) and Anderson et al, (2000). Solutions observed in all these models 
appear as invading traveling waves of cancer cells. 
Ferreira, and Martins (2002), Reaction diffusion model for the growth of a vascular tumor, nutrient 
limited mode for a vascular cancer growth including cell proliferation motility and death was presented. 
12
 
developed  mathematical models that describes the reduction in volume of vascular tumor in response to specific 
chemotherapeutic administration strategies. The model consists of a system of partial differential equations 
governing intratumoral drug concentration 
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2.0 MODEL EQUATIONS  
We propose to consider the de Pillis et al (2002) and Jackson (2002) models which include immunotherapy in 
addition to chemotherapy for vascular tumor growth. Using their models, we  study the two coupled sets of 
equations, the first of which  models the immune and drug interactions with the tumor and   
The two important models from Jackson (2002) are given as: 
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where d is the drug and n is the tumour cells, 
while the models from de Pillis et al (2002) for tumor growth, drug used, Natural killer and CD8
+
 and 
the tumor signal equations are given as: 
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Here H is the standard heaviside step function 
 
2.2 ASSUMPTIONS  
In line with the assumptions and analysis of de Pillis et al (2002) and Jackson (2002), we make the following 
assumptions for the model equations of vascular tumor growth. 
• The tumor cells are uniformly susceptible to drug treatment and immune interactions and there is 
negligible necrosis in the tumor. 
• All cells and drugs within the tumor undergo diffusion and conversion. 
• Tumor cell grow exponentially in the absence of chemotherapy and immune response, this growth rate 
could be logistic. 
• The chemotherapeutic drug, the NK. Cells, the CD8+ cells and the circulating lymphocytes all become 
inactive over time at rates proportional to their population size. 
• NK cells, CD8+ cells and the drug can all kill tumor cells. 
• The interaction with tumor cells inactivates some fraction of the NK and the CD8+ cells. 
• The presence of a tumor activates both NK and CD8+ cells.  
• A chemical signal generated by the tumor tissue attracts NK and CD8+ cells.  
• Circulating lymphocytes stimulate the growth of CD8+ cells and NK cells and increase at some constant 
rate. 
• The drug kills NK, CD8+ and circulating lymphocytes in addition to the tumor cells. The drugs diffuse 
between the tumor cells.  
We define the following dependents variables for use in the equations of the model: 
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),( trT   Density of tumor cells within the tumor Where r  is the radius of the tumour, t  is the time 
),( trV  Density of vasculature within the tumor 
),( trD  Concentration of drug within the tumor tissue  
),( trN  Density of NK cells within the tumor tissue  
),( trC  Density of CD8
+
 cells 
),( trS  Concentration of chemical signal that attract immune cells 
),( trU  Local cell velocity inside the tumor 
),( trP  Internal pressure inside tumor 
tDb  
Concentration of drug in blood streams 
)(tDN   
Concentration of drug in normal tissue surrounding the tumor 
)(tN N  
Density of NK cells in normal tissue surrounding the tumor 
)(tCN  
Density of CD8
+
 cells in normal tissue 
)(tL  Density of circulating lymphocytes in the blood stream 
NL  
Amount of NK cells that is removed from normal cells as a result of death by chemotherapy In the 
model also, we used the following parameters: 
di  Diffusion or cell motility constant for population i . 
`iλ  Natural growth or death rate for population i . 
Ui  Rate at which the drug is inactivated in its interaction with population’s i . 
CN LL ,  
Rate at which NK and CD8
+
 cells are inactivated from interaction within the tumor. 
CN aa ,  
Attraction coefficient for NK and CD8
+
 cells in response to the tumor signal. 
sα  Rate of signal production by tumor cells. 
 
We Restate the de Pillis et al (2002) models for tumor growth, drug used, Natural killer and CD8
+
 and the tumor 
signal equations, given as: 
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where H is the standard heaviside step function 
To be able to have any meaningful analytical study of these modeled equations,  introduction of some 
modifications in the form of assumptions are necessary. The I function used above represents the interaction 
terms between the various populations within the tumor. For example, ),( TDIDT represents the interaction 
between the drug and the tumor cells, which we expect to depend only on the local concentration D and T. It is 
also assumed that the interaction has the same effect on each population involved up to some scaling multiplier.  
We equally assumed that each local species is subject both to diffusion and to conventions resulting from the 
local cell velocity. The tumor cells have some natural growth rate but are killed by the drug and the immune cells. 
The drug decays at some constant rate, diffuses into (or out of) the tumor from the blood stream, and is 
deactivated at some rate in its interactions with both the tumor cells and immune cells. Each immune cell 
population undergoes natural death or inactivation as well as death or inactivation resulting from its interaction 
with the tumor cells and the drug. In addition, it is assumed that the tumor secretes a chemical that attract the 
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body’s immune cells and this chemical decays at some natural rate and is produced only within the tumor 
boundary. 
From (2.1), we see that 
),(),()(2 TNILTCLLDTITTd
t
T
NTNCTCDTTT −−−+∇=∂
∂ λ   
where 
T      =  the Tumor population 
TdT
2∇   =  Diffusion terms 
`TTλ   =  growth rate of tumor 
),( TDIDT  =  Death of tumor as a result of drugs 
),( TCTI CTC     =  Tumor removed as CD8
+ 
acts on it 
),( TNIL NTN    =  Death of tumor as NK acts on it. 
We also have equation (2.2) as: 
),(),(),())((2 DNIUDCIUTDIUDtDDDd
t
D
NDNCDCDTTbDD −−−−Γ+−∇=∂
∂ λ where  
D           =  the chemotherapeutic drug 
DdD
2∇  =  Diffusion terms 
Dλ        =  the decay rate  
))(( DtDb −Γ   =  from vasculature  
),( TDIU DTT    = the number of Tumor cells that are being removed as a result of the drug 
),( DCIU CDC  =   introduction of the  CD8
+  
as a result of the drug 
),( DNIU NDN   = Inactivation of the NK as the result of the drug 
Equation (2.3 )and (2.4 )also are presented respectively as: 
),(),().( 2 DNITNIiNNdSNa
t
N
NDNTNNNN −−−∇=∇∇+∂
∂ λ  
N   =  Represents our natural killer NK 
).( SNaN ∇∇  =  Signal gradient  
Nd N
2∇  =  Diffusion of the NK 
NNλ−  =  Natural death of NK 
),( TNIi NTN  =  Is the inactivation co-efficient of NK in T 
),( DNI ND  =  Death from drug introduction of NK in the prevention of D 
and 
),(),().( 2 DCITCIiCCdSCa
t
C
CDcTcCcC −−−∇=∇∇+∂
∂ λ  
C   =  Represents the CD8+ cells 
).( SCaC ∇∇  =  the signal gradient  
Cd c
2∇  =  the diffusion within the cells  of the CD8+ 
CCλ   =  the natural death rate of the CD8+ 
),( TCIi CTC  =  Inactivation factor of the CD8
+  
in T 
),( DCICD  =  the death from drug inactivation of CD8
+ 
in the prevention of D 
 
2.2.1  INITIAL CONDITIONS  
We introduce the following parameters to be used in specifying the initial conditions of the system. 
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oT  Initial density of tumor cells  
oV  Initial density of vasculature 
oD  Initial concentration of drug in the blood stream 
oo CN & Initial concentration of NK and CD8
+
 cells in the body tissue 
oL  Initial concentration of circulating lymphocytes cells in the body tissue. 
 We suppose that initially the only populations present in the tumor itself are the tumor and the tumor 
vasculature. 
Systematically, we suppose that initially, there is no drug and that there are specified population of NK cells, 
CD8
+
 cells and circulating lymphocytes and so we have:  
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We define the tumor boundary as a level surface of some function ),( trB  where: 
( ) 0,,),( =−= tRrtrB φθ                                                                    (2.7) 
The motion of a point on the boundary 0),( =trB  is then determined by 
,. vv nu
dt
dr
n ⋅=                                                    (2.7b) 
where vn  is an outward normal vector to the tumor boundary. This equation (2.7b) represents the equation of 
motion of the drug concentration within the tumour where “u” is the local cell velocity. We connect the temporal 
and spatial temporal equations through continuity conditions at the boundary. Therefore, at the boundary
0),( =trB , we have 
)(),(),(),(),(),( tCtrCtNtrNtDtrD NNrN ===       (2.8) 
We need to introduce a new set of parameters to be used in the interaction terms  
ki  As the susceptibility of population i to the drug 
iσ  Is the drug saturation coefficient for population i  
We now give appropriate definitions for the interaction function Iij in the equations. Based on the analysis 
presented in the de Pillis et al (2002) we model the tumor immune cell interaction as product terms 
NTI
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=
=
 
For the drug’s interaction with the tumor and the immune cells, in both the systemic and local area we follow the 
exponential model presented by de-Pillis et al (2002). We change the derivation slightly so that the kill fraction 
in a time interval from t  to tt ∆+  is  
tek
tP
tPttP D ∆−=−∆+ − )1(
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        (2.9) 
where P  is some cell population. Rearranging and taking the limit as t∆  goes to 0 , we have: 
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Thus, we take the local drug-cell interaction terms to be: 
Journal of Pharmacy and Alternative Medicine                                                                                                                                 www.iiste.org 
ISSN 2222-4807 (online) ISSN 2222-5668 (Paper) An International Peer-reviewed Journal 
Vol.6, 2015 
 
12 





−=
−=
−=
−
−
−
CekI
NekI
TekI
D
CCD
D
NND
D
TDT
C
N
T
)1(
)1(
)1(
σ
σ
σ
       (2.11)
 
We now consider this model in the case of complete spherical symmetry, so that there is no angular dependence 
to any of the spatially dependence variables, and now the tumor boundary is determined by 
0)(),( =−= tRrtrB . Then (4.1), (4.2), (4.3), (4.4) and (4.5) become : 
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The initial boundary of the tumor is now given by 0Rr = , and its evolution now follows  
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NON- DIMENSIONALIZATION  
We now introduce dimensionless variables and parameters as defined below 
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Substituting equation (2.18) into the equation (2.12) – (2.16) yields after simplification and dropping the bars for 
convenience, the following equations:  
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These are the modeled equations for the drug-cells interaction on the tumor described here as inhibited growth.. 
The evolution of the tumor boundary is as specified above. 
 
2.1 SOLUTIONS OF THE MODEL  
We now consider analytic solutions to our model. We seek solutions to our model equation for the delay period 
using additional sets of assumptions. 
 
2.2 DRUG-INHIBITED TUMOR GROWTH  
We now suppose that the intra tumor drug concentration D is constant, so that equation (2.19) becomes 
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∂
dsdsus
ss
)(
1 2
2
 
∫ ⋅−⋅ dsS
S
uSuS
s
r
3
2
0
2
2
21
   
 (Integration by paths) we have  
uuuudsu
r
322
0
=+=−= ∫  
Therefore, we hold that 
∫ =∂
∂
udsus
ss
3)(
1 2
2
 
Also,  
( )[ ] ( )[ ] rr DrTDrT sekdsek TT
00
1111∫
−−
−−=−−  
= ( )[ ] ( ) 011 ∗−−− − rek DrT T  ( )[ ]reku DrT T−−−= 113  
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( )
r
ek
u
Dr
T
T
3
11
−
−−
=  
( ( ))
3
11)(
r
ekru DT
Tσ−
−−=  - - - - -                (2.2.2) 
Then applying (2.17) we now have  
( ) ( ( ) ),(
3
11
),( tR
ek
ttRu
dt
dR
D
T
Tσ−
−−
=  - -                     (2.2.3) 
tek
o
DT
TeRtR
))1(1(
)(
σ−
−−
=   - - - -                   (2.2.4) 
ANALYTIC SOLUTION OF LOCAL DRUG EQUATION  
We make similar assumption regarding the chemotherapy drug to obtain analytic solution. We assume that drug 
diffuses much faster than the tumor grows. We again consider the case in which there is no local immune 
presence, so that 0== CN  
This yield the normalized equation  
( ) ( )( ) 0111 2
2
=−+−Γ−−





∂
∂
∂
∂
−
TekUDDD
dr
D
r
rr
D
TTBD
D
Tσλ      (2.2.15) 
subject to the initial boundary condition 0)0( =rD and )()( tDtDR N=  
If we assume low drug concentrations, then De T
DT σσ =− −1
  and we have
 
( ) B
D
TTTD
D
D
d
DTkU
dr
D
r
rr
Γ−=+Γ+−





∂
∂
∂
∂ 111 2
2
σλ  
Let  
D
TTTD
D
d
TkU σλξ +Γ+=2         (2.2.16) 
Then the non-homogeneous PDE above becomes  
)(
1 22
2
tD
d
D
r
D
r
rr
B
D
D
Γ
−=−





∂
∂
∂
∂ ξ  
A particular solution to the equation is  
)(
2
tD
d
D B
DDξ
Γ
=  
So that the homogeneous equation is  
 
022 =− Dm ξ  
22
Dm ξ=  
 
DD CoshtbSinhtatrD ξξ )()(),( +=  
The general solution will be  
)(2
)()(),( tB
DD
DD D
d
CoshtbSinhtatrD ξξξ
Γ
++=  
  where )(ta  and )(tb DD etbetam
ta
D
ξξξ −+=±= )()( )(  are constants   or 
)(221
),( tB
DD
tt
D
d
eCeCtrD DD ξ
ξξ Γ++= −  
At 0),( =trD  we require that 0)( =tb   
or  02 =C ,  )(tRr =  
02 =−′′ FF Dξ
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B
DD
D D
d
SinhtattRD
2
)()),(( ξξ
Γ
+=  
or )(21)),(( tB
DD
t
D
d
eCttRD D ξ
ξ Γ+=  
B
DD
rr D
d
DCoshtbDSinhtatrD
2
)()(),( ξξξ
Γ
++=  At 0)0( =Dr  requires that 0)( =tb  
At )(tRr =  
)()()),((
2
tD
dR
DRSinh
tattRD B
DDξ
ξ Γ
+=  
Theorem: 
If RQf →+:  is continuous and RQU →+:  is a solution of the following non-homogenous 
initial/boundary value problem 
[ ]





==
∈=
=−
0),1(),0(
1,0,0)0,(
),(),(),(
tUtU
xxU
txftxUtxU xxt
 
for every [ ]1,0∈t    where  
{ }=∞<<<<∈=+ txIRtxQ 0,10:),( 2  closure of +Q
 
Now for every [ )∞∈ ,0P  
Let 0=− xxt HH  ( ) [ ] [ ]∞∈ ,1,0, PXtx  
( ) ),(,, PxfPtxH =  [ )1,0∈x  
0),,1(),,0( == PtHPtH  [ )∞∈ ,Pt  
Then U  and H  satisfy 
( )∫=
t
dpPtxHtxU
0
,,),(  
We shall adopt the techniques in the Duhamel principle to solve (2.23) after some modification. Hence, 
),().( 2 DCLliCCdSCa
t
C
CDcTcCcC −−−∇=∇∇+∂
∂ λ  
The parameters cccc iNa ,,, λ  and cDl  are as defined previously. 
),().( 2 DCLliCCdSCa
t
C
CDcTcCcC −−−∇=∇∇+∂
∂ λ         (2.3.1) 
).(2 SCaLliCCd
t
C
CCDcTcCc ∇∇−−−−=∇−∂
∂ λ  
Set  ),().( txfSCaLliC CCDcTcC =∇∇−−−− λ  
),(2 txfCd
t
C
c =∇−∂
∂
        (2.3.2) 
as stated in Duhamel principle 
),(2
2
2
txf
x
C
d
t
C
c =∂
∂
−
∂
∂
 
We adopt the same boundary conditions in Duhamel’s principle with  
),(),( txctxu =  
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∫=
t
dpPtxHtxC
0
),,(),(  
We have 
02 =− xxNt HdH  [ ] [ ]∞×∈ ,1,0),( ptx       (2.3.3) 
So let )()()(),,( pYtTxXptxH =  
YTXH
YTXH
xx
t
′′=
=
&
 
Substituting in (2.3.3) 
TYXdYTX ′′= 2&  
02 =
′′
−
X
X
d
T
T
c
&
 
Let 
22 k
X
X
d
T
T
c =
′′
−
&
 
2k
T
T
=
&
          (2.3.4) 
1
2
1
2
λ
λ
+
=
+=
k
eT
kInT
 
and  
22 m
X
X
d c =
′′
 
2
2
1
m
dX
X
c
=
′′
 
Xm
d
X
c
2
2
1
=′′  
02 =
′′
−
X
X
d
T
T
c
&
 
0
2
1
=
′′
−
X
X
T
T
dc
&
 
2
2
1
m
X
X
T
T
dc
=
′′
−
&
 
Therefore, 
2
2
1
m
T
T
dc
−=
&
        (2.3.4) 
and 
2m
X
X
−=
′′
          (2.3.5) 
From (2.3.4) 
22 md
T
T
c=
&
 
1
22 λ+= tmdInT c  
1
22 λ+
=
tmdceT   let βλ =1e  
1
22
),(
tmdcetxT β=          (2.3.6) 
02 =+′′ XmX  
The auxiliary equation now will become  
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022 =+ mk  
mk ±=  
mxmx eAeAxX 21)( +=
−
 
( ) )()()()(),,( 2221 pYeeAeApYtTxXptxH tmdmxmx Cβ+== −  
( ) dpeAeAeptxH kxkxtmdC ϕβ 212 2),,( +=⇒ −  
( ) ∫+= −
t
kxkxtmd dpeAeAe C
0
21
2 2 ϕβ  
( ) )(212 2 teAeAe kxkxtmdC ϕβ += −  
( ) teAeAeptxH kxkxtmdC ϕβ 212 2),,( += −        (2.3.7) 
 
3.0      ANALYSIS AND DISCUSSION 
In this analysis, we used collected data to test for the validity of the models most especially the tumor growth in 
the presence and non-presence of chemotherapy. In the case of the non-usage of chemotherapy to control the 
growth of the tumour cells, we called it the un-inhibited tumour growth and the other we call the inhibited 
tumour growth. We shall carry out our analysis in these lines to study the interaction of the chemotherapy and 
immunology with the cancer cells. The necessary amounts of drugs which can manage the growth rate of tumor 
so that it can be considered to be at dormant stage so as not to kill the host for a long period is also studied. 
 
3.1 CHEMOTHERAPY TREATMENT 
Tumor left untreated would grow to a dangerous level. In equations (2.1.2) – (2.1.6), we modeled some set of 
equations with pulse chemotherapy administration into the body after the tumor is large enough to be detected. 
In these models, we consider chemotherapy as the only external treatment and expected to control the tumour 
growth. We examined the tumor response to pulse chemotherapy by incrementing pulses. 
 
3.3 Inhibited Tumour Growth 
Here we consider the treatment with chemotherapy to see if the cancer cell proliferation can be controlled or 
eradicated. In Fig. 4, we can see that with this treatment, the tumour cells boundary reduces over varied levels of 
drug administration. However, using a single dose of drug over time shows that the cell boundary increases after 
sometime, (Fig. 2 & 3). This shows that the administration of the chemotherapy can control the proliferation of 
the cancer cells in a patient if it is administered at varied levels of the drug but we must be careful of the level of 
the drug to be used.  
Furthermore, Fig. 5 shows that as the tumour boundary increases, we require higher levels of the drug 
to control the cell proliferation. This suggests and confirms the requirement that patients should come forward 
for treatment as quickly as possible to reduce the level of drug treatment.  
 
3.4 CONCLUSION 
It is our hope that, these models with their analytic solutions will give better understanding of the growth pattern 
of cancer cells and the control procedures for the clinicians and medical Doctors treating the cancer cell 
proliferations in a patient.  
We equally saw that drug doses cannot be administered arbitrarily. Individuals has to be tested to 
ascertain the health level before drug is administered.  
 
3.5 RECOMMENDATION  
We recommend these models to those in the medical field to enhance their efficient control of cancer in their 
patients. A lot of progresses are being made in that field, but we still recommend that, these models should be 
considered to prevent frequent loss of life resulting from treatment of tumour/cancer of any kind due to wrong 
levels of drug administered. 
 We are aware that since most of the modeled equations are non-linear, one of the best methods of 
solution would have been the Numerical approach. Yet, we used analytical method to demonstrate those 
simplified assumptions valid for cancerous tumours, like the ineffectiveness of the Natural Killer, CD8
+
 and the 
cytotoxic lymphocytes, in controlling cancerous cells. Therefore, one can attempt studying these same models 
using other methods different from analytical approach.  
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